Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Shimena R Li, Terence O'Keeffe, Mazen S. Zenati, Joshua D. Brown, Katherine M. Reitz, Matthew D. Neal, Gary Vercruysse, Bellal Joseph, Raminder Nirula, Francis X. Guyette, Brian S. Zuckerbraun, Brian J. Eastridge, Jason L. Sperry
Publikováno v:
Ann Surg
OBJECTIVE We sought to characterize the timing of administration of prehospital tranexamic acid (TXA) and associated outcome benefits. BACKGROUND TXA has been shown to be safe in the prehospital setting post-injury. METHODS We performed a secondary a
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Amer H. Zureikat, David L Bartlett, Kenneth K. Lee, Mazen S. Zenati, Nathan Bahary, Alessandro Paniccia, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
Ann Surg Oncol
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3263486cc36ea0870e151d9eee750612
https://europepmc.org/articles/PMC8614241/
https://europepmc.org/articles/PMC8614241/
Autor:
Andrew B. Peitzman, Joshua B. Brown, Mazen S. Zenati, Brian S. Zuckerbraun, Barbara J. Early-Young, Clifton W. Callaway, Donald M. Yealy, Louis H. Alarcon, Matthew D. Neal, Peter W. Adams, Bellal Joseph, Brian J. Eastridge, Jason L. Sperry, Raquel M. Forsythe, Matthew R. Rosengart, Timothy R. Billiar, Raminder Nirula, Terence O'Keeffe, Francis X. Guyette, Gary Vercruysse
Publikováno v:
JAMA Surg
IMPORTANCE: In-hospital administration of tranexamic acid after injury improves outcomes in patients at risk for hemorrhage. Data demonstrating the benefit and safety of the pragmatic use of tranexamic acid in the prehospital phase of care are lackin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c71926d44abebcbdf44aa5ba77e2fff
https://europepmc.org/articles/PMC7536625/
https://europepmc.org/articles/PMC7536625/
Autor:
Melissa E. Hogg, Amer H. Zureikat, Mazen S. Zenati, Mark D. Girgis, Ahmad Hamad, Jonathan C. King, Herbert J. Zeh
Publikováno v:
Annals of surgery. 274(3)
OBJECTIVE Compare oncologic outcomes after open and robotic pancreatic resections for pancreatic adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA Receipt of adjuvant chemotherapy improves survival after resected PDAC. Complications after pancreatect
Autor:
Nathan Bahary, Caroline J. Rieser, Herbert J. Zeh, Mazen S. Zenati, Kenneth K. Lee, Amer H. Zureikat, Hao Liu, Aatur D. Singhi, Amr Al-abbas, Melissa E. Hogg
Publikováno v:
Ann Surg Oncol
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for f
Autor:
Virginia Falvello, Nathan Bahary, Herbert J. Zeh, Amer H. Zureikat, Ashika Mani, Mazen S. Zenati, Amr I. Al Abbas, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Journal of surgical oncologyREFERENCES.
BACKGROUND AND OBJECTIVES Ampullary adenocarcinoma (AA) is classified by immunohistochemical (IHC) subtypes into intestinal (IN), pancreatobiliary (PB), and ambiguous (AM). The impact of adjuvant therapy on IHC subtype and disease stage is unclear. W
Autor:
Matthew P. Holtzman, Melissa E. Hogg, J. Wallis Marsh, David L. Bartlett, James F. Pingpank, Mashaal Dhir, Amer H. Zureikat, David A. Geller, M. Haroon A. Choudry, Herbert J. Zeh, Heather L. Jones, Mazen S. Zenati, Nathan Bahary, Allan Tsung
Publikováno v:
Annals of Surgical Oncology. 25:550-557
In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver me